No Data
Yifan Pharmaceutical (002019.SZ): The approval notice for the supplemental application of Abeggsitin α injection has been received.
On March 21, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its holding subsidiary Yiyisheng Biological Pharmaceutical (Peking) Co., Ltd. received the approval notice of the supplementary application for the α injection of Aibeigesiting (referred to as "Yili Shuh") from the National Pharmaceutical Administration on March 21, 2025. After the approval of this supplementary application, the administration time of Yili Shuh has changed from 48 hours after chemotherapy to 24 hours after chemotherapy. This will provide the company’s product Yili Shuh with a differentiated competitive advantage, helping to expand market share and enhance brand influence. At the same time, the change in administration timing after chemotherapy allows patients to
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Yifan Pharmaceutical Secures Drug Registration for Ambroxol Drug
Yifan Pharmaceutical (002019.SZ): Obtained the pharmaceutical registration certificate for Ambroxol oral solution.
On March 10, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Suzhou Yifan Pharmaceutical Co., Ltd. received the "Pharmaceutical Registration Certificate" for the oral solution of Ambroxol from the National Medical Products Administration on March 10, 2025. The Ambroxol oral solution is a medication for respiratory system diseases. It is used to treat acute and chronic respiratory diseases associated with spasmodic contractions, changes in secretion formation, and impaired secretion transport, particularly spastic bronchitis, emphysematous bronchitis, and bronchial asthma. According to data from Minai Network, the domestic sales of Ambroxol oral solution in the first half of 2024 are...
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Surges 3.5%; Individual Investors Who Own 49% Shares Profited Along With Insiders
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Not Quite Adding Up